U.S. Markets closed

AMAG Pharmaceuticals, Inc. (AMAG)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
18.20+0.45 (+2.54%)
At close: 4:00PM EDT

18.20 0.00 (0.00%)
After hours: 4:34PM EDT

People also watch
ACORALNYAKRXANACMNTA

AMAG Pharmaceuticals, Inc.

1100 Winter Street
Waltham, MA 02451
United States
617-498-3300
http://www.amagpharma.com

SectorHealthcare
IndustryDiagnostic Substances
Full Time Employees545

Key Executives

NameTitlePayExercisedAge
Mr. William K. HeidenChief Exec. Officer and Director1.18MN/A57
Mr. Edward H. Myles MBAChief Financial Officer, Sr. VP of Fin. and Treasurer434.9kN/A45
Mr. Joseph D. Vittiglio Esq.Sr. VP of Legal Affairs, Technical Operations & Quality, Gen. Counsel and Sec.528.06kN/A45
Dr. Julie Krop M.D.Chief Medical Officer and Sr. VP of Clinical Devel. & Regulatory Affairs567.37kN/A51
Mr. Nicholas GrundChief Commercial Officer and Exec. VP772.39kN/A47
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for women’s health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Corporate Governance

AMAG Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 2. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.